ATE384263T1 - Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen - Google Patents

Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen

Info

Publication number
ATE384263T1
ATE384263T1 AT01931796T AT01931796T ATE384263T1 AT E384263 T1 ATE384263 T1 AT E384263T1 AT 01931796 T AT01931796 T AT 01931796T AT 01931796 T AT01931796 T AT 01931796T AT E384263 T1 ATE384263 T1 AT E384263T1
Authority
AT
Austria
Prior art keywords
target cells
biological agents
living target
determining biological
determining
Prior art date
Application number
AT01931796T
Other languages
English (en)
Inventor
Manuel Vega
Original Assignee
Nautilus Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nautilus Biotech filed Critical Nautilus Biotech
Application granted granted Critical
Publication of ATE384263T1 publication Critical patent/ATE384263T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01931796T 2000-05-09 2001-05-04 Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen ATE384263T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0005852A FR2808804B1 (fr) 2000-05-09 2000-05-09 Procede de determination du titre d'agents biologiques en temps reel dans des cellules cibles vivantes et ses applications

Publications (1)

Publication Number Publication Date
ATE384263T1 true ATE384263T1 (de) 2008-02-15

Family

ID=8849996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01931796T ATE384263T1 (de) 2000-05-09 2001-05-04 Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen

Country Status (6)

Country Link
US (2) US20030175694A1 (de)
EP (1) EP1281081B1 (de)
AT (1) ATE384263T1 (de)
DE (1) DE60132443D1 (de)
FR (1) FR2808804B1 (de)
WO (1) WO2001086291A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US20060251619A1 (en) * 2005-05-04 2006-11-09 Gilles Borrelly Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
KR101248252B1 (ko) 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
EP2461162A1 (de) * 2010-12-03 2012-06-06 Texcell, . Verfahren zur Bestimmung des Titers von Viren durch Verwendung von infektiösen Standardsubstanzen
WO2020028639A1 (en) 2018-08-01 2020-02-06 Essen Instruments, Inc. D/B/A Essen Bioscience, Inc. Methods, kits and stain compositions for flow cytometry evaluation of unassociated virus-size particles using multiple fluorogenic dyes
US11137337B2 (en) * 2019-01-21 2021-10-05 Essen Instruments, Inc. Flow cytometry with data analysis for optimized dilution of fluid samples for flow cytometry investigation
WO2020197644A1 (en) 2019-03-26 2020-10-01 Essen Instruments, Inc. D/B/A Essen Bioscience, Inc. Flow cytometry evaluation for unassociated non-enveloped viral particles
US11709116B2 (en) 2020-02-04 2023-07-25 Sartorius Bioanalytical Instruments, Inc. Liquid flourescent dye concentrate for flow cytometry evaluation of virus-size particles and related products and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671559B1 (fr) * 1991-01-14 2002-09-27 Ct Nal Rech Scient Sequences codant pour le recepteur beta3-adrenergique murin, leur utilisation comme sondes et pour l'expression de peptides, vecteurs, hotes cellulaires contenant ledit vecteur, et applications desdits peptides.
US6183997B1 (en) * 1997-03-21 2001-02-06 Stratagene Polymerase enhancing factor (PEF) extracts PEF protein complexes isolated PEF proteins and methods for purifying and identifying same
WO1999011764A2 (en) * 1997-09-05 1999-03-11 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
FR2802645B1 (fr) * 1999-12-16 2002-03-08 Meillat Roland Methode d'evaluation de la performance d'un ensemble d'agents biologiques dans des cellules cibles vivantes et ses applications
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones

Also Published As

Publication number Publication date
US7349812B2 (en) 2008-03-25
EP1281081B1 (de) 2008-01-16
EP1281081A1 (de) 2003-02-05
DE60132443D1 (de) 2008-03-06
US20030175694A1 (en) 2003-09-18
FR2808804B1 (fr) 2002-08-02
FR2808804A1 (fr) 2001-11-16
WO2001086291A1 (fr) 2001-11-15
US20060195268A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
ATE384263T1 (de) Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE373092T1 (de) Zusammensetzungen und verfahren zur behandlung von chlamydia-infektionen
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60235464D1 (de) Knochenmarkersatzmaterial-verbundwerkstoff, verfahren zu seiner herstelllung und kit
DE50214416D1 (de) Vermehrung von viren in zellkultur
WO2002084250A3 (en) Methods for mass spectrometry detection and quantification of specific target proteins in complex biological samples
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
ATE232399T1 (de) Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen
ATE349533T1 (de) Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
ATE186575T1 (de) Verfahren zur identifizierung von menschlichen und tierischen zellen mit der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
AP2368A (en) Novel expression vectors and uses thereof.
DE60117297D1 (de) Genetischer test zur identifizierung von trägern komplexer vertebraler missbildungen in rindern
ATE452984T1 (de) Verfahren und zusammensetzungen zur extraktion von proteinen aus zellen
ATE371037T1 (de) Testsystem zur bestimmung von gentoxizitäten
ATE329638T1 (de) Vorrichtung, um in einem zielgebiet eines menschlichen oder tierischen körpers einen künstlichen isolierten kreislauf zu etablieren
ATE315107T1 (de) Verfahren und kit zur früherkennung von krebs
BR112023024627A2 (pt) Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas
EP1587928A4 (de) Menschliches saa3-nukleinsäuremolekül, -protein und verwendungsverfahren dafür
DE60116772D1 (de) Verfahren zum anonymen registrieren, speichern und verwenden von körpermaterial und/oder davon abgeleiteter information
WO2004013634A3 (en) Dna damage repair polypeptide and uses thereof
DE60029017D1 (de) Verwendung von blauen kupferproteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties